ArticleJournal of the American Heart Association2025
Income-Level and Immigrant Status Are Associated With Discontinuation of Evidence-Based Secondary Prevention Therapies After Myocardial Infarction.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevalence and factors influencing medication adherence after acute myocardial infarction: a systematic review and meta-analysis.International journal of clinical pharmacy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMechanisms for worse prognosis after myocardial infarction in low socioeconomic status are unclear. We therefore investigated the association between socioeconomic status and discontinuation of evidence-based secondary prevention drug therapies.
methodsAll patients with a first-ever myocardial infarction, on treatment with a statin (n=60 717), antithrombotic therapy (n=65 862), or a renin-angiotensin-aldosterone-system inhibitor (n=51 486) at the routine 1-year visit in SWEDEHEART (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies) between January 2006 and mid-2020 were included in this population-based nationwide cohort study. Individual-level socioeconomic status was measured by disposable income quintile, region of birth, and educational level. Outcomes were discontinuation (>180 days without a new prescription claim) of statins, antithrombotic therapies, and renin-angiotensin-aldosterone-system-inhibitors. Bias-minimized multivariable adjusted hazard ratios (aHRs) were estimated during follow-up until December 2020.
resultsDiscontinuation occurred more often in the lowest versus highest income quintile for statins (aHR, 1.25 [95% CI, 1.20-1.31]), antithrombotic therapy (aHR, 1.26 [95% CI, 1.20-1.32]), and renin-angiotensin-aldosterone-system inhibitors (aHR, 1.32 [95% CI, 1.26-1.39]). Discontinuation of statins was more frequent among immigrants (versus nonimmigrants) born in other Nordic (aHR, 1.24 [95% CI, 1.17-1.32]), other European (aHR, 1.40 [95% CI, 1.33-1.47]), Asian (aHR, 1.45 [95% CI, 1.36-1.56]), and other world regions (aHR, 1.63 [95% CI, 1.45-1.84]). Associations between immigrant background and discontinuation of antithrombotic therapies and renin-angiotensin-aldosterone-system inhibitors were even stronger. Lower (versus tertiary) educational level was inversely associated with discontinuation of secondary prevention drug classes.
conclusionsDespite Swedish universal health care, discontinuation of evidence-based drugs post myocardial infarction is strongly associated with disposable income and immigrant background. Further study on strategies to improve adherence in low socioeconomic status post myocardial infarction is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.